Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study

Ai Cui, Anhui Shi, Lei Deng, Yanyan Sun, Jiayi Yu, Xinrong Lian, Ziyue Zhao · 2026

Read Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study by Ai Cui, Anhui Shi, Lei Deng, Yanyan Sun, Jiayi Yu, Xinrong Lian, Ziyue Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13541139.txt.

Description

Ai Cui and six co-authors shared a trial protocol in twenty twenty-six. It tests if a lung-fibrosis drug can prevent radiation injury. The patients have lung cancer. Radiation pneumonitis and later fibrosis limit how hard tumors can be hit. Nintedanib is approved for idiopathic pulmonary fibrosis. It targets the same fibrotic pathways as the injury. That match is why the team chose it.

Sixty-six patients will be randomized at three Chinese centers. All have unresectable stage two to three disease. Half get the drug just before chemoradiation starts. They stay on it for twelve weeks. Half form the control group. Randomization is balanced across chemotherapy regimens. The protocol sets efficacy and safety endpoints for prevention. Past signs hint at an answer, but no prospective trial has settled it. The results are not yet in. Results will decide if prophylaxis joins standard chemoradiation.

Catalog record

CREATORAi Cui, Anhui Shi, Lei Deng, Yanyan Sun, Jiayi Yu, Xinrong Lian, Ziyue Zhao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13541139

Browse the full library · About the Tower of Babel